TA
TOVX icon

Teachers Advisors’s Theriva Biologics TOVX Stock Holding History

Teachers Advisors’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-14
Closed -$76K – 3166
2017
Q1 		$76K Hold
14
– – ﹤0.01% 3008
2016
Q4 		$92K Hold
14
– – ﹤0.01% 3017
2016
Q3 		$207K Hold
14
– – ﹤0.01% 2875
2016
Q2 		$216K Buy
+14
New +$264K ﹤0.01% 2863

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Teachers Advisors's TOVX Position: Q2 2017 in Review

Teachers Advisors sold out of Theriva Biologics (TOVX) in Q2 2017, closing a stake of 14 shares — an estimated $76K sold.

Teachers Advisors first reported a position in TOVX in Q2 2016 and held it in 4 quarters. The position peaked at $216K in Q2 2016. 53 funds tracked by Wall St. Rank hold TOVX as of Q2 2017.

  • Teachers Advisors reported no remaining Theriva Biologics position as of Q2 2017 after selling out during the quarter.
  • Teachers Advisors sold 14 Theriva Biologics shares in Q2 2017, an estimated $76K.
  • Teachers Advisors first reported a position in Theriva Biologics in Q2 2016 and held it in 4 quarters.
  • Teachers Advisors's Theriva Biologics position peaked at $216K in Q2 2016.
  • 53 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2017.

Based on Teachers Advisors's 13F filing for Q2 2017, filed 10 Aug 2017.